Otelixizumab
|
Otelixizumab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Chimeric + Humanized |
| Target | ? |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Otelixizumab is a chimeric/humanized monoclonal antibody which it is used as an immunosuppresive drug.
| Chimeric + humanized monoclonal antibodies |
|---|
| Dorlixizumab, Otelixizumab |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)





